Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

291 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sustained molecular remission in a patient with CML in blastic crisis receiving dose-reduced hematopoietic stem-cell transplantation followed by early withdrawal of cyclosporine and prophylactic use of interferon-alpha.
Hamaki T, Kami M, Momomura S, Mineishi S, Kusumi E, Kanda Y, Ueyama J, Miyakoshi S, Morinaga S, Takaue Y, Mutou Y. Hamaki T, et al. Among authors: takaue y. Am J Hematol. 2002 Nov;71(3):196-9. doi: 10.1002/ajh.10203. Am J Hematol. 2002. PMID: 12410575 Free article.
Successful engraftment after reduced-intensity umbilical cord blood transplantation for adult patients with advanced hematological diseases.
Miyakoshi S, Yuji K, Kami M, Kusumi E, Kishi Y, Kobayashi K, Murashige N, Hamaki T, Kim SW, Ueyama J, Mori S, Morinaga S, Muto Y, Masuo S, Kanemaru M, Hayashi T, Takaue Y, Taniguchi S. Miyakoshi S, et al. Among authors: takaue y. Clin Cancer Res. 2004 Jun 1;10(11):3586-92. doi: 10.1158/1078-0432.CCR-03-0754. Clin Cancer Res. 2004. PMID: 15173064
Allogeneic hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen for treatment of metastatic renal cell carcinoma: single institution experience with a minimum 1-year follow-up.
Nakagawa T, Kami M, Hori A, Kim SW, Murashige N, Hamaki T, Kishi Y, Fujimoto H, Matsuoka N, Okajima E, Komiyama M, Tobisu K, Wakayama T, Uike N, Tajima K, Makimoto A, Mori S, Tanosaki R, Takaue Y, Kakizoe T. Nakagawa T, et al. Among authors: takaue y. Exp Hematol. 2004 Jul;32(7):599-606. doi: 10.1016/j.exphem.2004.04.006. Exp Hematol. 2004. PMID: 15246155 Free article.
Early central nervous system complications after reduced-intensity stem cell transplantation.
Kishi Y, Miyakoshi S, Kami M, Ikeda M, Katayama Y, Murashige N, Kusumi E, Yuji K, Kobayashi K, Kato D, Hamaki T, Matsumura T, Kim SW, Morinaga S, Mori S, Kanemaru M, Hayashi T, Takaue Y, Taniguchi S; Tokyo Stem Cell Transplantation Consortium. Kishi Y, et al. Among authors: takaue y. Biol Blood Marrow Transplant. 2004 Aug;10(8):561-8. doi: 10.1016/j.bbmt.2004.05.004. Biol Blood Marrow Transplant. 2004. PMID: 15282534 Free article.
Incidence of invasive aspergillosis after allogeneic hematopoietic stem cell transplantation with a reduced-intensity regimen compared with transplantation with a conventional regimen.
Kojima R, Kami M, Nannya Y, Kusumi E, Sakai M, Tanaka Y, Kanda Y, Mori S, Chiba S, Miyakoshi S, Tajima K, Hirai H, Taniguchi S, Sakamaki H, Takaue Y. Kojima R, et al. Among authors: takaue y. Biol Blood Marrow Transplant. 2004 Sep;10(9):645-52. doi: 10.1016/j.bbmt.2004.06.003. Biol Blood Marrow Transplant. 2004. PMID: 15319776 Free article.
Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan.
Saito AM, Kami M, Mori S, Kanda Y, Suzuki R, Mineishi S, Takami A, Taniguchi S, Takemoto Y, Hara M, Yamaguchi M, Hino M, Yoshida T, Kim SW, Hori A, Ohashi Y, Takaue Y. Saito AM, et al. Among authors: takaue y. Am J Hematol. 2007 Oct;82(10):873-80. doi: 10.1002/ajh.20977. Am J Hematol. 2007. PMID: 17570513 Free article. Clinical Trial.
291 results